194 related articles for article (PubMed ID: 37084385)
1. Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.
Largeot A; Klapp V; Viry E; Gonder S; Fernandez Botana I; Blomme A; Benzarti M; Pierson S; Duculty C; Marttila P; Wierz M; Gargiulo E; Pagano G; An N; El Hachem N; Perez Hernandez D; Chakraborty S; Ysebaert L; François JH; Cortez Clemente S; Berchem G; Efremov DG; Dittmar G; Szpakowska M; Chevigné A; Nazarov PV; Helleday T; Close P; Meiser J; Stamatopoulos B; Désaubry L; Paggetti J; Moussay E
Blood; 2023 Jun; 141(26):3166-3183. PubMed ID: 37084385
[TBL] [Abstract][Full Text] [Related]
2. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
[TBL] [Abstract][Full Text] [Related]
3. PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.
Yeomans A; Lemm E; Wilmore S; Cavell BE; Valle-Argos B; Krysov S; Hidalgo MS; Leonard E; Willis AE; Forconi F; Stevenson FK; Steele AJ; Coldwell MJ; Packham G
Oncotarget; 2016 Nov; 7(46):74807-74819. PubMed ID: 27579538
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
5. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
Yuan G; Chen X; Liu Z; Wei W; Shu Q; Abou-Hamdan H; Jiang L; Li X; Chen R; Désaubry L; Zhou F; Xie D
J Exp Clin Cancer Res; 2018 Feb; 37(1):21. PubMed ID: 29415747
[TBL] [Abstract][Full Text] [Related]
6. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
7. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
[TBL] [Abstract][Full Text] [Related]
8. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.
Zhang W; Kater AP; Widhopf GF; Chuang HY; Enzler T; James DF; Poustovoitov M; Tseng PH; Janz S; Hoh C; Herschman H; Karin M; Kipps TJ
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18956-60. PubMed ID: 20956327
[TBL] [Abstract][Full Text] [Related]
9. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.
Taylor J; Wilmore S; Marriot S; Rogers-Broadway KR; Fell R; Minton AR; Branch T; Ashton-Key M; Coldwell M; Stevenson FK; Forconi F; Steele AJ; Packham G; Yeomans A
Cell Signal; 2022 Jun; 94():110311. PubMed ID: 35306137
[TBL] [Abstract][Full Text] [Related]
10. Activation of
Biran A; Yin S; Kretzmer H; Ten Hacken E; Parvin S; Lucas F; Uduman M; Gutierrez C; Dangle N; Billington L; Regis FF; Rassenti LZ; Mohammad A; Hoffmann GB; Stevenson K; Zheng M; Witten E; Fernandes SM; Tausch E; Sun C; Stilgenbauer S; Brown JR; Kipps TJ; Aster JC; Gnirke A; Neuberg DS; Letai A; Wang L; Carrasco RD; Meissner A; Wu CJ
Cancer Res; 2021 Dec; 81(24):6117-6130. PubMed ID: 34686499
[TBL] [Abstract][Full Text] [Related]
11. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
Chen R; Zhu M; Chaudhari RR; Robles O; Chen Y; Skillern W; Qin Q; Wierda WG; Zhang S; Hull KG; Romo D; Plunkett W
Leukemia; 2019 Jul; 33(7):1663-1674. PubMed ID: 30700841
[TBL] [Abstract][Full Text] [Related]
12. FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity.
Qureshi R; Yildirim O; Gasser A; Basmadjian C; Zhao Q; Wilmet JP; Désaubry L; Nebigil CG
PLoS One; 2015; 10(11):e0141826. PubMed ID: 26536361
[TBL] [Abstract][Full Text] [Related]
13. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.
Pozzo F; Bittolo T; Vendramini E; Bomben R; Bulian P; Rossi FM; Zucchetto A; Tissino E; Degan M; D'Arena G; Di Raimondo F; Zaja F; Pozzato G; Rossi D; Gaidano G; Del Poeta G; Gattei V; Dal Bo M
Leukemia; 2017 Nov; 31(11):2407-2415. PubMed ID: 28321119
[TBL] [Abstract][Full Text] [Related]
14. Targeting the eIF4F translation initiation complex for cancer therapy.
Konicek BW; Dumstorf CA; Graff JR
Cell Cycle; 2008 Aug; 7(16):2466-71. PubMed ID: 18719377
[TBL] [Abstract][Full Text] [Related]
15. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
[TBL] [Abstract][Full Text] [Related]
16. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
17. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
18. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis.
Lin CJ; Nasr Z; Premsrirut PK; Porco JA; Hippo Y; Lowe SW; Pelletier J
Cell Rep; 2012 Apr; 1(4):325-33. PubMed ID: 22573234
[TBL] [Abstract][Full Text] [Related]
19. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
Pelletier J; Graff J; Ruggero D; Sonenberg N
Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
[TBL] [Abstract][Full Text] [Related]
20. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle.
Caraballo JM; Acosta JC; Cortés MA; Albajar M; Gómez-Casares MT; Batlle-López A; Cuadrado MA; Onaindia A; Bretones G; Llorca J; Piris MA; Colomer D; León J
Oncotarget; 2014 Jul; 5(13):4694-708. PubMed ID: 25051361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
